Bridging Pharmacy and Medicine: A Collaborative Approach to Drug-Induced Liver Injury

Location

Suwanee, GA

Start Date

6-5-2025 1:00 PM

End Date

6-5-2025 4:00 PM

Description

Drug-induced liver Injury (DILI) is one of the leading causes of acute liver failure and poses a significant challenge in drug development and clinical practice. Clinical presentation of patients can vary from hepatomegaly, jaundice, and ascites to the dangerous outcome of encephalopathy. While the actual incidence is difficult to report, the annual reported incidence of DILI is 15-20 per 100,000 a year. Alarming enough, there is a large discrepancy between the common drugs associated with DILI and the number of prescriptions for these medications each year. Common medicines like Amoxicillin/Clavulanate, a first-line antibiotic, were prescribed approximately 28.7 million times in 2022, and even the drug class statins with 237.9 million prescriptions between 2010-2011 that have only increased due to the health crisis, with Atorvastatin prescribed 110 million times during 2022. We strive to enhance the understanding of healthcare professionals about DILI, its phenotypes, and strategies to minimize its risk in clinical settings across a multi-disciplinary team and relate these effects with five commonly implicated drugs associated with DILI. By informing multiple healthcare providers about the dangers associated with DILI and educating patients alike, we aim to promote awareness of DILI.

Embargo Period

5-19-2025

Comments

Presented by Katherine Fadus

This document is currently not available here.

COinS
 
May 6th, 1:00 PM May 6th, 4:00 PM

Bridging Pharmacy and Medicine: A Collaborative Approach to Drug-Induced Liver Injury

Suwanee, GA

Drug-induced liver Injury (DILI) is one of the leading causes of acute liver failure and poses a significant challenge in drug development and clinical practice. Clinical presentation of patients can vary from hepatomegaly, jaundice, and ascites to the dangerous outcome of encephalopathy. While the actual incidence is difficult to report, the annual reported incidence of DILI is 15-20 per 100,000 a year. Alarming enough, there is a large discrepancy between the common drugs associated with DILI and the number of prescriptions for these medications each year. Common medicines like Amoxicillin/Clavulanate, a first-line antibiotic, were prescribed approximately 28.7 million times in 2022, and even the drug class statins with 237.9 million prescriptions between 2010-2011 that have only increased due to the health crisis, with Atorvastatin prescribed 110 million times during 2022. We strive to enhance the understanding of healthcare professionals about DILI, its phenotypes, and strategies to minimize its risk in clinical settings across a multi-disciplinary team and relate these effects with five commonly implicated drugs associated with DILI. By informing multiple healthcare providers about the dangers associated with DILI and educating patients alike, we aim to promote awareness of DILI.